Citations

Clear

1134 citation(s) found for "Li, Yan".

Factors influencing post-surgical survival in degenerative mitral regurgitation
Butcher, Steele C. , Essayagh, Benjamin , Benfari, Giovanni , Antoine, Clémence , Roussel, Jean‐Christian , Wijngaarden, Aniek Van, Tribouilloy, Christophe , Ruşinaru, Dan, Topilsky, Yan , Michelena, Héctor I. , Delgado, Victoria , Enriquez‐Sarano, Maurice , Topilsky, Yan , Benfari, Giovanni , Roussel, Jean-Christian , Tribouilloy, Christophe , Hochstadt, Aviram , Michelena, Hector I , Enriquez-Sarano, Maurice , Delgado, Victoria , Topilsky, Yan , Essayagh, Benjamin , Butcher, Steele C , Steyerberg, Ewout W. , Grigioni, Francesco , Tourneau, Thierry Le , Marsan, Nina Ajmone , Bax, Jeroen J.

Mayo Clinic

European Heart Journal | January 4, 2023 | Volume: 44 | Issue: 10 | Pages: 871-881

10.1093/eurheartj/ehad004 | PMID 36702625 Get It

Abstract Aims Indications for surgery in patients with degenerative mitral regurgitation (DMR) are increasingly liberal in all clinical guidelines but the role of secondary outcome determinants (left atrial volume index ≥60 mL/m2, atrial fibrillation, pulmonary artery systolic pressure ≥50 mmHg and moderate to severe tricuspid regurgitation) and their impact on post-operative outcome remain disputed. Whether these secondary outcome markers are just reflective of the DMR severity or intrinsically affect survival after DMR surgery is uncertain and may have critical importance in the management of patients with DMR. To address these gaps of knowledge the present study gathered a large cohort of patients with quantified DMR, accounted for the number of secondary outcome markers and examined their independent impact on survival after surgical correction of the DMR. Methods and results The Mitral Regurgitation International DAtabase-Quantitative registry includes patients with isolated DMR from centres across North America, Europe, and the Middle East. Patient enrolment extended from January 2003 to January 2020. All patients undergoing mitral valve surgery within 1 year of registry enrolment were selected. A total of 2276 patients [65 (55–73) years, 32% male] across five centres met study eligibility criteria. Over a median follow-up of 5.6 (3.6 to 8.7) years, 278 patients (12.2%) died. In a comprehensive multivariable Cox regression model adjusted for age, EuroSCORE II, symptoms, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LV ESD) and DMR severity, the number of secondary outcome determinants was independently associated with post-operative all-cause mortality, with adjusted hazard ratios of 1.56 [95% confidence interval (CI): 1.11–2.20, P = 0.011], 1.78 (95% CI: 1.23–2.58, P = 0.002) and 2.58 (95% CI: 1.73–3.83, P < 0.0001) for patients with one, two, and three or four secondary outcome determinants, respectively. A model incorporating the number of secondary outcome determinants demonstrated a higher C-index and was significantly more concordant with post-operative mortality than models incorporating traditional Class I indications alone [the presence of symptoms (P = 0.0003), or LVEF ≤60% (P = 0.006), or LV ESD ≥40 mm (P = 0.014)], while there was no significant difference in concordance observed compared with a model that incorporated the number of Class I indications for surgery combined (P = 0.71). Conclusion In this large cohort of patients treated surgically for DMR, the presence and number of secondary outcome determinants was independently associated with post-surgical survival and demonstrated better outcome discrimination than traditional Class I indications for surgery. Randomised controlled trials are needed to determine if patients with severe DMR who demonstrate a cardiac phenotype with an increasing number of secondary outcome determinants would benefit from earlier surgery.
TCF-1 controls Treg functions that regulate inflammation, CD8 T-cell cytotoxicity, and severity of colon cancer
Khazaie, Khashayarsha , Osman, Abu , Yan, Bingyu, Kazemian, Majid , Gounari, Fotini

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 119.16-119.16

10.4049/jimmunol.208.supp.119.16 Get It

Abstract The transcription factor TCF-1 is essential for the development and function of T regulatory (Treg) cells, however its function is poorly understood. Here, we show that TCF-1 primarily suppresses transcription of genes that are co-bound by Foxp3. Single-cell RNA-seq analysis identified effector- and central-memory Treg-cells with differential expression of Klf2 and memory and activation markers. TCF-1 deficiency did not change the core Treg transcriptional signature, but promoted alternative signaling pathways whereby Treg-cells became activated and gained gut-homing and TH17 characteristics. TCF-1-deficient Treg-cells strongly suppressed T-cell proliferation and cytotoxicity, but were compromised in controlling CD4+ T-cell polarization and inflammation. In mice with polyposis, Treg cell-specific TCF-1 deficiency promoted tumor growth. Consistently, tumor-infiltrating Treg cells of colorectal cancer patients showed lower TCF-1 expression and increased TH17 expression signatures compared to adjacent normal tissue and circulating T-cells. Thus, Treg cell-specific TCF-1 expression differentially regulates TH17-mediated inflammation and T-cell cytotoxicity, and can determine colorectal cancer outcome. Supported by NIH R01 AI 108682 (FG & KK), NIH RO1 AI 147652 (FG), NIH R35GM138283 (MK), and Praespero Innovation Award Alberta, Canada (FG & KK)
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Molloy, Mark P. , Morris, John C. , Berman, Sarah , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Day, Gregory S. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Mori, Hiroshi , Perrin, Richard J. , Levey, Allan I. , Masters, Colin L. , Fagan, Anne M. , Bateman, Randall J. , Martins, Ralph N. , Network, and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Levey, Allan I , Pedrini, Steve , Xiong, Chengjie , Benzinger, Tammie L.S. , Karch, Celeste M. , Cruchaga, Carlos , Lee, Jae‐Hong , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Teunissen, Charlotte E. , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | December 28, 2022 | Volume: 19 | Issue: 7 | Pages: 2790-2804

10.1002/alz.12879 | PMID 36576155 Get It

Abstract Background Glial fibrillary acidic protein (GFAP) is a promising candidate blood‐based biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its disease‐associated changes, its clinical correlates, and biofluid‐type dependency will influence its clinical utility. Methods We evaluated plasma, serum, and cerebrospinal fluid (CSF) GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Results Plasma GFAP elevations appear a decade before expected symptom onset, after amyloid beta (Aβ) accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished Aβ‐positive from Aβ‐negative ADAD participants and showed a stronger relationship with Aβ load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Conclusion Our findings support a role for plasma GFAP as a clinical biomarker of Aβ‐related astrocyte reactivity that is associated with cognitive decline and neurodegeneration. Highlights Plasma glial fibrillary acidic protein (GFAP) elevations appear a decade before expected symptom onset in autosomal dominant Alzheimer's disease (ADAD). Plasma GFAP was associated to amyloid positivity in asymptomatic ADAD. Plasma GFAP increased with clinical severity and predicted disease progression. Plasma and serum GFAP carried similar information in ADAD, while cerebrospinal fluid GFAP did not.
The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum
Essayagh, Benjamin , Benfari, Giovanni , Antoine, Clémence , Grigioni, Francesco , Tourneau, Thierry Le , Roussel, Jean‐Christian , Bax, Jeroen J. , Delgado, Victoria , Wijngaarden, Aniek Van, Tribouilloy, Christophe , Ruşinaru, Dan, Topilsky, Yan , Thapa, Prabin , Topilsky, Yan , Le Tourneau, Thierry , Marsan, Nina Ajmone , Tribouilloy, Christophe , Hochstadt, Aviram , Topilsky, Yan , Michelena, Hector I , Enriquez-Sarano, Maurice , Delgado, Victoria , Bax, Jeroen J , Benfari, Giovanni , Topilsky, Yan , Essayagh, Benjamin , Grigioni, Francesco , Marsan, Nina Ajmone , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

Circulation | December 27, 2022 | Volume: 147 | Issue: 10 | Pages: 798-811

10.1161/circulationaha.122.062612 | PMID 36573420 Get It

Background: Mitral valve prolapse (MVP) is responsible for a considerable disease burden but is widely heterogeneous. The lack of a comprehensive prognostic instrument covering the entire MVP spectrum, encompassing the quantified consequent degenerative mitral regurgitation (DMR), hinders clinical management and therapeutic trials. Methods: The new Mitral Regurgitation International Database Quantitative (MIDA-Q) registry enrolled 8187 consecutive patients (ages 63±16 years, 47% women, follow-up 5.5±3.3 years) first diagnosed with isolated MVP, without or with DMR quantified prospectively (measuring effective regurgitant orifice [ERO] and regurgitant volume) in routine practice of 5 tertiary care centers from North America, Europe, and the Middle East. The MIDA-Q score ranges from 0 to 15 by accumulating guideline-based risk factors and DMR severity. Long-term survival under medical management was the primary outcome end point. Results: MVP was associated with DMR absent/mild (ERO <20 mm 2 ) in 50%, moderate (ERO 20–40 mm 2 ) in 25%, and severe or higher (ERO ≥40 mm 2 ) in 25%, with mean ERO 24±24 mm 2 , regurgitant volume 37±35 mL. Median MIDA-Q score was 4 with a wide distribution (10%–90% range, 0–9). MIDA-Q score was higher in patients with EuroScore II ≥1% versus <1% (median, 7 versus 3; P < 0.0001) but with wide overlap (10%–90% range, 4–11 versus 0–7) and mediocre correlation ( R 2 0.18). Five-year survival under medical management was strongly associated with MIDA-Q score, 97±1% with score 0, 95±1% with score 1 to 2, 82±1% with score 3 to 4, 67±1% with score 5 to 6, 60±1% with score 7 to 8, 44±1% with score 9 to 10, 35±1% with score 11 to 12, and 5±4% with MIDA-Q score ≥13, with hazard ratio 1.31 [1.29–1.33] per 1-point increment. Excess mortality with higher MIDA-Q scores persisted after adjustment for age, sex, and EuroScore II (adjusted hazard ratio, 1.13 [1.11–1.15] per 1-point increment). Subgroup analysis showed persistent association of MIDA-Q score with mortality in all possible subsets, in particular, with EuroScore II<1% (hazard ratio, 1.08 [1.02–1.14]) or ≥1% (hazard ratio, 1.11 [1.08–1.13]) and with no/mild DMR (hazard ratio, 1.14 [1.10–1.19]) or moderate/severe DMR (hazard ratio, 1.13 [1.10–1.16], all per 1-point increment with P <0.0001). Nested-model and bootstrapping analyses demonstrated incremental prognostic power of MIDA-Q score (all P <0.0001). Conclusions: This large, international cohort of isolated MVP, with prospective DMR quantification in routine practice, demonstrates the wide range of risk factor accumulation and considerable heterogeneity of outcomes after MVP diagnosis. The MIDA-Q score is strongly, independently, and incrementally associated with long-term survival after MVP diagnosis, irrespective of presentation, and is therefore a crucial prognostic instrument for risk stratification, clinical trials, and management of patients diagnosed with all forms of MVP.
Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma
Yang, Pei‐Yu , Xu, Weiling , Liang, Xinyue , Yu, Shanshan , Yi, Xingcheng , Liu, Mengmeng , Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Zhang, Nan , Wang, Jingxuan , Hu, Rui , Kumar, Shaji , Jin, Fengyan , Kumar, Shaji K , Dai, Yun , Jin, Fengyan , Yue, Tingting, Zhang, Yingjie , Guo, Qiang , Sun, Xiaoxiao , Dai, Yun

Mayo Clinic

American Journal of Hematology | December 21, 2022 | Volume: 98 | Issue: 3 | Pages: No page available

10.1002/ajh.26810 | PMID 36540935 Get It

IDENTIFICATION AND INVESTIGATION OF SENESCENT CELLS IN SKELETAL MUSCLE AGING
Habiballa, Leena , Aversa, Zaira, Ng, Yan Er, Zhang, Xu , Ng, Yan Er , Passos, João F. , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 446-447

10.1093/geroni/igac059.1746 Get It

Abstract Skeletal muscle aging is marked by the loss and atrophy of resident fibers, and the accumulation of functionally diverse cell types including fibroblasts, adipocytes, and immune cells. Senescent cells amass in multiple tissues with advancing age where they contribute to aging, chronic disease, and physical decline. The role of senescence in mediating muscle aging has become a popular and sometimes contentious topic. However, to date, this concept has not been methodically tested. In this study, we characterized the changes in cell abundance and, importantly, cell-specific transcriptional profiles with skeletal muscle aging using scRNAseq. Interestingly, we identified a small population of p16 positive fibro-adipogenic progenitors (FAPs) which, upon further investigation using immunohistochemical methods, were found to express other senescence markers. This subpopulation of FAPs did not exhibit elevation in p21 levels with age. Instead, terminally differentiated myofibers were the source of the p21 increase. Myofibers with high p21 expression exhibit a strong inflammatory phenotype, which includes activated p53 signaling pathways together with strong cytokine-cytokine receptor interactions. We further identified large amounts of cross-talk between different cell types, suggesting that senescent FAPs and myofibers could contribute to skeletal muscle aging in a paracrine manner. Importantly, these observations in mice were confirmed in human samples, suggesting the strong translational power of these findings.
IDENTIFICATION AND INVESTIGATION OF SENESCENT CELLS IN SKELETAL MUSCLE AGING
Habiballa, Leena , Aversa, Zaira, Ng, Yan Er, Zhang, Xu , Ng, Yan Er , Passos, João F. , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 447-447

10.1093/geroni/igac059.1747 Get It

Abstract Skeletal muscle aging is marked by the loss and atrophy of resident fibers, and the accumulation of functionally diverse cell types including fibroblasts, adipocytes, and immune cells. Senescent cells amass in multiple tissues with advancing age where they contribute to aging, chronic disease, and physical decline. The role of senescence in mediating muscle aging has become a popular and sometimes contentious topic. However, to date, this concept has not been methodically tested. In this study, we characterized the changes in cell abundance and, importantly, cell-specific transcriptional profiles with skeletal muscle aging using scRNAseq. Interestingly, we identified a small population of p16 positive fibro-adipogenic progenitors (FAPs) which, upon further investigation using immunohistochemical methods, were found to express other senescence markers. This subpopulation of FAPs did not exhibit elevation in p21 levels with age. Instead, terminally differentiated myofibers were the source of the p21 increase. Myofibers with high p21 expression exhibit a strong inflammatory phenotype, which includes activated p53 signaling pathways together with strong cytokine-cytokine receptor interactions. We further identified large amounts of cross-talk between different cell types, suggesting that senescent FAPs and myofibers could contribute to skeletal muscle aging in a paracrine manner. Importantly, these observations in mice were confirmed in human samples, suggesting the strong translational power of these findings.
IDENTIFICATION AND INVESTIGATION OF SENESCENT CELLS IN SKELETAL MUSCLE AGING
Habiballa, Leena , Aversa, Zaira, Ng, Yan Er, Zhang, Xu , Ng, Yan Er , Passos, João F. , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 196-196

10.1093/geroni/igac059.785 Get It

Abstract Skeletal muscle aging is marked by the loss and atrophy of resident fibers, and the accumulation of functionally diverse cell types including fibroblasts, adipocytes, and immune cells. Senescent cells amass in multiple tissues with advancing age where they contribute to aging, chronic disease, and physical decline. The role of senescence in mediating muscle aging has become a popular and sometimes contentious topic. However, to date, this concept has not been methodically tested. In this study, we characterized the changes in cell abundance and, importantly, cell-specific transcriptional profiles with skeletal muscle aging using scRNAseq. Interestingly, we identified a small population of p16 positive fibro-adipogenic progenitors (FAPs) which, upon further investigation using immunohistochemical methods, were found to express other senescence markers. This subpopulation of FAPs did not exhibit elevation in p21 levels with age. Instead, terminally differentiated myofibers were the source of the p21 increase. Myofibers with high p21 expression exhibit a strong inflammatory phenotype, which includes activated p53 signaling pathways together with strong cytokine-cytokine receptor interactions. We further identified large amounts of cross-talk between different cell types, suggesting that senescent FAPs and myofibers could contribute to skeletal muscle aging in a paracrine manner. Importantly, these observations in mice were confirmed in human samples, suggesting the strong translational power of these findings.
The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration
Acuna‐Narvaez, Rachel, Heuer, Hilary W. , Forsberg, Leah K. , Alward, Anne, Graham, Danielle , Fishman, Ann, Nelson, Kevin M., Kolander, Tyler, Fillit, Howard , Galpern, Wendy R., Hung, Serena, Mason, Chris, Mignon, Laurence, Yan, Ni , Simen, Arthur A. , Tesseur, Ina, Tsai, Richard , Yeh, Felix L. , Mester, Carly , Ljubenkov, Peter A. , Rosen, Howard J. , Boxer, Adam L. , Pearlman, Rodney , Mitic, Laura L. , Investigators, NSP Site, Boeve, Bradley F. , Investigators, NSP Site

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S5 | Pages: No page available

10.1002/alz.064959 Get It

AbstractBackgroundIn familial frontotemporal lobar degeneration (f‐FTLD), plasma levels of neurofilament light (NfL) are elevated at least two years prior to symptom onset and predict future clinical status. The Neurofilament Surveillance Project (NSP), an actively recruiting observational study, seeks to obtain higher resolution data of temporal changes in plasma NfL to better understand its clinical utility in f‐FTLD interventional trials. The NSP is a pre‐competitive collaboration sponsored by the Bluefield Project to Cure FTD and funded by biotechnology and pharmaceutical companies and nonprofit organizations.MethodParticipants must be members of families with disease‐causing mutations in C9orf72, MAPT or GRN and enrolled in the ALLFTD natural history study. Up to 335 participants, with roughly equal representation across mutation type, provide plasma quarterly for 3 years (4355 samples total) to enable the observation of peripheral NfL levels longitudinally during disease onset and progression. Plasma is collected by certified mobile research nurses during remote visits, and NfL is measured in batch at least every 6 months. NfL measurements from one plasma aliquot per draw will be correlated with annual assessments obtained in the ALLFTD study, including measures of disease severity (CDRÒ+NACC‐FTLD, CGI, etc.), cognitive function from the UDS Neuropsychology Battery, and volumetric MRI data. Additional plasma aliquots are reserved for future analyses of other biomarkers during the course of the study; another subset of aliquots is reserved to share with interested investigators after the study ends.ResultAs of 1/19/22, the NSP had enrolled 161 participants, including 62 from C9orf72 kindreds, 60 from MAPT kindreds, and 28 from GRN kindreds. One‐hundred forty‐five participants had completed their initial visit, and 109 had completed more than 3, and up to 5, quarterly blood draws. Enrollment and study visits are ongoing despite COVID‐related limitations.ConclusionThe quarterly blood sampling from this study, combined with annual comprehensive clinical assessments through the ALLFTD natural history study, will enable a more detailed understanding of when and how NfL levels change during phenoconversion and/or disease progression in f‐FTLD mutation carriers. These data will be especially informative in the context of the targeted investigational therapeutics for f‐FTLD now entering clinical trials.
Contributions of remote, unsupervised dyadic subjective measures to identify older adults with Mild Cognitive Impairment
Nosheny, Rachel L. , Jin, Chengshi , Knight, Krissy N, Banh, Timothy, Howell, Taylor, Truran‐Sacrey, Diana, Fockler, Juliet , Bui, Chau, Gummadi, Shilpa, Santhakumar, Jessica , Ashford, Miriam T. , Camacho, Monica R. , Flenniken, Derek , Moulder, Krista L., Li, Yan , Petersen, Ronald C. , Carrillo, Marı́a C., Mackin, R. Scott , Weiner, Michael W. , Roberson, Erik D. , Morris, John C. , Stricker, Nikki H. , Rabinovici, Gil D. , Neuhaus, John M

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S7 | Pages: No page available

10.1002/alz.061353 Get It

AbstractBackgroundDyadic (self and study partner) subjective reports of an individual’s recent cognitive and functional decline are an efficient approach to facilitate identification of older adults with, and at risk for, Mild Cognitive Impairment (MCI). Such methods can be easily adapted for remote administration, but few studies have investigated the ability of remotely‐collected, unsupervised dyadic subjective reports to accurately detect MCI and cognitive decline.MethodsIn 289 older adults enrolled in the Brain health Registry (BHR), with clinically‐confirmed diagnoses of Cognitively‐unimpaired (CU) or MCI, we identified the optimal combination of remote measures to accurately distinguish CU from MCI. We then externally validated our predictive model in 217 participants enrolled in a separate cohort, Validation of Online Methods to Predict Cognitive Decline (eVAL). Predictors included Cogstate Brief Battery One Card Learning (OCL) accuracy; self‐ and study partner‐reported memory concern (SMCs); performance on online adaptations of Everyday Cognition Scale (ECog, self‐ and study partner‐report versions), Geriatric Depression Scale Short Form (GDS); family history of AD, age, gender, and education. We calculated 10‐fold cross validated area under the ROC curves (cvAUC), 95% confidence intervals (CI), and the percentage of participants correctly classified (accuracy) for all models. Likelihood ratio (LR) tests were used to compare model fits.ResultsIn the BHR cohort, models including dyad‐report ECog, family history of AD, GDS, and Cogstate OCL scores distinguished CU from MCI with the highest accuracy (cvAUC = 0.90; 95% CI = 0.83, 0.92; accuracy = 85.5%). Models excluding study partner‐report ECog distinguished diagnostic groups with moderate accuracy (cvAUC = 0.83; 95% CI = 0.78, 0.85; accuracy = 75.9%) When applied to the validation cohort, the optimal training model including dyadic report performed with moderate accuracy ( Table 2 ). In the validation cohort, inclusion of study partner (but not self) report SMC, in addition to dyadic‐report ECog, improved model fit (LR test p<0.01).ConclusionsRemotely‐collected dyadic subjective measures, along with other remote measures, accurately distinguish CU from MCI. Subjective cognitive and functional decline and concerns about memory problems independently contribute to diagnostic discrimination. Results support future utilization of remote dyadic subjective measures to efficiently identify older adults with MCI for prodromal AD clinical trials, and in clinical care settings.